Table 2.

Outcomes of 1232 Acute Liver Failure Patients with Grade III/IV Hepatic Encephalopathy treated with (n=97) or without (n=1135) Therapeutic Hypothermia.

		No Hypothermia Control Group (N=1135)		Hypothermia group (N=97)
		N	Number (%)	N	Number (%)	P value
ICU Complications (7-days)
Seizures		1135	93 (8.2%)	97	13 (13.4%)	0.08
Arrhythmias		1135	310 (27.3%)	97	37 (38.1%)	0.03*
Gastrointestinal bleeding		1135	138 (12.2%)	97	12 (12.4%)	0.95
Acute Respiratory Distress Syndrome		1134	24 (2.1%)	97	4 (4.1%)	0.20
Abnormal CT of head		319	132 (41.4%)	80	42 (52.5%)	0.08
Abnormal Chest X-ray		1091	837 (76.7%)	94	82 (87.2%)	0.02
Bacteremia/Blood stream infection		1135	207 (18.2%)	97	16 (16.5%)	0.67
Tracheal aspirate infection		1135	264 (23.3%)	97	20 (20.6%)	0.55
Listed for LT		1132	452 (39.9%)	96	42 (43.8%)	0.46
Received LT		1129	277 (24.5%)	97	17 (17.5%)	0.12
Time to Hospital Discharge
From enrollment to home/other facility (days)		439	12.0 (8.0 – 18.0)	35	16.0 (11.0 – 20.0)	0.03
21-day spontaneous survival		1135	446(39.3%)	97	44 (45.4%)	0.24
Overall Survival		1135	679 (59.8%)	97	60 (61.9%)	0.70
Acetaminophen
Transplanted		533	65 (12.2%)	61	6 (9.8%)	0.59
21 day spontaneous survival		537	298 (55.5%)	61	35 (57.4%)	0.78
21 day overall survival		537	354 (65.9%)	61	41(67.2%)	0.84
Non-acetaminophen
Transplanted		596	212 (35.6%)	36	11 (30.6%)	0.54
21 day spontaneous survival		598	148 (24.8%)	36	9 (25%)	0.90
21 day overall survival		598	325 (54.3%)	36	19 (52.8%)	0.85

• *When comparing arrhythmias following initiation of TH, there was no significant difference between the two groups (control 27% vs. TH 28%, p=0.9).